This article was originally published in Start Up
By combining quantum chemistry and computing power, QuantumBio Inc. says it can model large macromolecules far better and more efficiently than currently available mechanics-based software. The company's tools promise better predictability of chemical and physical properties for virtual screening, QSAR, ADME/Tox, lead optimization and docking.
You may also be interested in...
Ask a head of R&D for a pharma or biotech to name the area where the need for new and better tools is greatest, and likely as not the answer will be predictive modeling of a drug's ADME/Tox profile. There's an abundance of sweet spots across the preclinical landscape for companies with better models and predictive tools.
A new publication offers up proof of concept that the genetic signatures of microorganisms found in blood and tumor tissue could improve precision medicine cancer diagnostics. The study also bolsters the notion that targeting the microbiome could lead to innovative cancer therapies.
A better understanding of heme trafficking could lead to drug targets in metabolic diseases, anemias, porphyrias, hemolytic diseases such as sickle cell disease – even parasitic infections.